Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising?
Author:
Affiliation:
1. Medical Oncology Department University of Navarra Clinic Madrid Spain
Publisher
Wiley
Subject
Cancer Research,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32520
Reference30 articles.
1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay J;Int J Cancer,2015
2. ESMO‐ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease;Colombo N;Ann Oncol,2019
3. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs;Haslam A;JAMA Netw Open,2019
4. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer;Zhang L;N Engl J Med,2003
5. Prognostic significance of tumor‐infiltrating T cells in ovarian cancer: a meta‐analysis;Hwang WT;Gynecol Oncol,2012
Cited by 41 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Genetically Engineered Probiotic Limosilactobacillus reuteri Releasing IL-22 (LR-IL-22) Modifies the Tumor Microenvironment, Enabling Irradiation in Ovarian Cancer;Cancers;2024-01-23
2. Characterizing the Immune Environment in Peritoneal Carcinomatosis: Insights for Novel Immunotherapy Strategies;Annals of Surgical Oncology;2023-11-23
3. New Achievements from Molecular Biology and Treatment Options for Refractory/Relapsed Ovarian Cancer—A Systematic Review;Cancers;2023-11-10
4. TRAF3 suppression encourages B cell recruitment and prolongs survival of microbiome-intact mice with ovarian cancer;Journal of Experimental & Clinical Cancer Research;2023-05-01
5. Efficacy and toxicity of carboplatin and gemcitabine administered on day 1 and day 8 (day1&8) versus day 1-only for platinum-sensitive recurrent epithelial ovarian cancer;International Journal of Gynecologic Cancer;2023-04-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3